Pathogenic BRCA1 and BRCA2 mutations confer high risks of breast and ovarian cancer. Variation in risk estimates by degree of family history suggests that these risks are modified by other genetic variants [1] [2] [3] [4] [5] . Recent studies from the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA) have demonstrated that common breast cancer susceptibility alleles, identified through genome-wide association studies (GWAS) in the general population [6] [7] [8] [9] , are also associated with the risk of developing breast cancer in BRCA1 or BRCA2 mutation carriers 10, 11 . However, although five of six alleles were associated with risk of breast cancer for BRCA2 mutation carriers, only two polymorphisms (in the TOX3 and 2q35 regions) were associated with risk for BRCA1 carriers. These findings are consistent with the distinct pathology of breast cancer in BRCA1 tumors 12, 13 and suggest that the genetic variants that modify breast cancer risk for BRCA1 mutation carriers may differ from the modifiers of risk for BRCA2 carriers or for non-carriers.
To search for genetic loci associated with breast cancer in BRCA1 carriers, we conducted a two-stage GWAS. In stage 1, we genotyped 2,500 BRCA1 carriers using the Illumina Infinium 610K array, which included 620,901 SNPs. Mutation carriers were selected on the basis of an invasive breast cancer diagnosis at under 40 years of age (n = 1,250) or the absence of breast cancer when 35 years of age or older (n = 1,250). After quality control exclusions, 2,383 carriers (1,193 unaffected and 1,190 affected) from 20 centers in 11 different countries and 555,616 SNPs were available for analysis (Supplementary Tables 1 and 2 ). Genotype associations were evaluated using a 1 degree-of-freedom (d.f.) score test for trend, based on modeling the retrospective likelihood of the observed genotypes conditional on the disease phenotypes, stratified by country of residence. A kinship-adjusted version of the score test statistic was used to allow for the dependence between related individuals.
There was little evidence for inflation in the test statistic of association (inflation factor (λ) = 1.036; Supplementary Fig. 1 ). Ninety-six SNPs were significant at the P < 10 −4 level compared with 55.6 SNPs which were expected by chance. In stage 2, we genotyped 86 of these SNPs, seven surrogate SNPs (within 10 kb of the significant SNPs and pair-wise r 2 > 0.90) and three additional SNPs in 6,332 BRCA1 carriers. After quality control exclusions, 89 SNPs and 5,986 BRCA1 mutation carriers (3,012 unaffected and 2,974 affected) were used in the stage 2 analysis. The most significant associations were for five SNPs on 19p13 (P < 0.002), which had hazard ratios in the same direction as in stage 1 ( Table 1 and Supplementary Table 3 ). In the combined analysis of stage 1 and 2, there was strong evidence of association 14 with breast cancer for these SNPs (P = 2.3 × 10 −9 to P = 3.9 × 10 −7 ).
The minor alleles of rs8170 and rs4808611 were associated with an increased breast cancer risk for BRCA1 carriers (per allele HR = 1.26, 95% CI 1.17-1.35 for both SNPs). In contrast, SNPs rs8100241, rs2363956 and rs3745185 were associated with decreased breast cancer risk (HR = 0.84, 95% CI 0.80-0.89 for rs8100241 and rs2363956; HR = 0.86, 95% CI 0.81-0.91 for rs3745185) ( Table 1) . The HR estimates for rs8170 and rs4808611 were similar in stages 1 and 2, but for rs8100241, rs2363956 and rs3745185, the HRs were stronger in stage 1; this may be due to the sample selection criteria for stage 1 or a 'winner's curse' effect 15 . There was no evidence of heterogeneity in the HR estimates among the countries of residence in stages 1 and 2 combined ( Fig. 1; rs8170 , P = 0.10; rs4808611, P = 0.14; rs8100241, P = 0.18; rs2363956, P = 0.17; and rs3745185, P = 0.48).
The strength of the association with breast cancer could also be affected by the inclusion of prevalent cases if these SNPs were 8 8 6 VOLUME 42 | NUMBER 10 | OCTOBER 2010 Nature GeNetics l e t t e r s associated with breast cancer survival. To address this possibility, we excluded breast cancer cases diagnosed with the disease >5 years before study entry. The HR estimates were similar to the overall analysis after this exclusion (Supplementary Table 4 ). This indicates that the inclusion of prevalent breast cancer cases was unlikely to have influenced the overall results.
To investigate whether any of these SNPs were associated with ovarian cancer risk for BRCA1 carriers, we analyzed the data within a competing risks framework and estimated HR simultaneously for breast and ovarian cancer. There was no evidence of association with ovarian cancer risk for any of the SNPs, and the breast cancer associations were virtually identical to the primary analysis both in terms of significance and in the HR estimates ( Table 2) . We repeated the breast cancer association analysis after excluding all individuals who developed ovarian cancer either before or after a breast cancer diagnosis. Despite the sample size reduction, the top four SNPs remained significant at P < 10 −7 and the HR estimates were identical to the analysis which included individuals with ovarian cancer as unaffected individuals (Supplementary Table 4 ). We also evaluated ovarian cancer associations after excluding individuals with ovarian cancer who were recruited >3 years after their cancer diagnosis in order to account for a potential survival bias. No significant associations were observed after this exclusion (P trend = 0.44 to P trend = 0.96 using competing risk analysis). We conclude that the associations with breast cancer were not confounded by the competing risk of ovarian cancer.
We evaluated the SNP associations by the predicted functional consequences of BRCA1 mutation type [16] [17] [18] . Class 1 mutations correspond to loss-of-function mutations and are expected to result in a reduced transcript or protein level due to nonsense-mediated RNA decay, whereas class 2 mutations are likely to generate stable proteins with potential residual or dominant negative function [18] [19] [20] . Among class 1 mutation carriers (combined stage 1 and 2, n = 5,732), the five most significant associated SNPs included rs6994019, an intronic SNP in MMP16 on chromosome 8 (P trend = 2.9 × 10 −6 ) and four SNPs in the 19p13 region (P trend = 7.6 × 10 −6 to P trend = 1.6 × 10 −4 ). The MMP16 SNP rs6994019 was the ninth most significant SNP in the primary analysis of all mutations combined (P trend = 2.7 × 10 −4 in stage 1 and 2 combined; Supplementary Table 3 ). The strongest association with breast cancer risk for carriers of class 2 mutations was at the five SNPs in the 19p13 region (P trend = 1.8 × 10 −6 to P trend = 1.2 × 10 −4 ; Supplementary Table 3 ). The HR estimates for the five SNPs in 19p13 were larger for class 2 mutations, but the differences between class 1 and class 2 mutations were significant for only rs8170 and rs3745185 (P = 0.03 and P = 0.004, respectively). These differences might reflect a stronger modifying effect on breast cancer risk for tumors retaining residual or dominant negative BRCA1 function.
Tumor estrogen or progesterone receptor status was available for 1,197 breast cancer cases in stage 1 and 2 combined. A caseonly analysis revealed significant differences in the associations for the 19p13 SNPs between estrogen receptor-positive and estrogen receptor-negative disease and between estrogen receptor-or progesterone receptor-positive and estrogen receptor-and progesterone receptor-negative disease, particularly for SNPs rs8100241, rs2363956 and rs3745185 (P = 0.002 to P = 0.04; Supplementary Table 5) . 
l e t t e r s
The OR estimates suggest that these SNPs are more strongly associated with estrogen receptor-negative disease. The two most significant SNPs (rs8170 and rs4808611) were strongly correlated (r 2 = 0.87) in the BRCA1 samples but displayed a low correlation with the other associated SNPs (r 2 < 0.23). rs8100241 and rs2363956 were perfectly correlated (r 2 = 1), whereas the least significant SNP, rs3745185, had weaker correlations with both sets of SNPs (r 2 = 0.17 and r 2 = 0.74 with rs8170 and rs8100241, respectively).
To evaluate the contribution of the 19p13 locus to breast cancer risk in the general population, we genotyped rs8170 and rs2363956 in 6,800 breast cancer cases and 6,613 controls from the SEARCH (Studies of Epidemiology and Risk Factors in Cancer Heredity) study in the UK. Neither SNP was associated with overall breast cancer risk (P = 0.65 and P = 0.79; Table 3 ). However, stratification of tumors by estrogen receptor status indicated that both SNPs were associated with estrogen receptor-negative breast cancer (rs8170, per-allele OR = 1.21, 95% CI 1.07-1.37, P = 0.0029 and rs2363956, OR = 0.83, 95% CI 0.75-0.92, P = 0.0003; Table 3 ). These effect sizes were similar to the estimated HRs for BRCA1 carriers, consistent with the observation that BRCA1 mutations predispose predominately to estrogen receptor-negative disease. Weaker associations were observed in the opposite direction for estrogen receptor-positive disease (rs8170, per-allele OR = 0.91, 95% CI 0.84-0.98, P = 0.011 and rs2363956, OR = 1.07, 95% CI 1.01-1.14, P = 0.016). Similar patterns were observed when tumors were stratified by progesterone receptor status or estrogen receptor and progesterone receptor status combined ( Table 3) .
The majority of breast tumors in BRCA1 carriers exhibit a triplenegative (estrogen receptor, progesterone receptor and HER2 negative) phenotype. To evaluate the association of the 19p13 locus with triple-negative disease in the general population, we obtained genotype data for the five SNPs from up to 2,301 cases from 15 centers in six countries involved in the triple-negative breast cancer consortium (TNBCC). Genotype data from up to 3,949 geographically matched controls were also available (Supplementary Table 5 ). All SNPs were associated with triple-negative breast cancer, and the ORs were comparable to the HRs seen in the BRCA1 carriers and the ORs for estrogen receptor-negative breast cancer seen in the SEARCH population-based study (rs2363956, per-allele OR = 0.80, 95% CI 0.74-0.87, P = 1.1 × 10 −7 and rs8170, OR = 1.28, 95% CI 1.16-1.41, P = 1.2 × 10 −6 ; Table 3 and Supplementary Table 5) .
Two of the SNPs (rs8170 and rs2366956) were genotyped in 2,486 BRCA2 mutation carriers as part of an ongoing GWAS. Neither SNP was associated with breast cancer risk for BRCA2 carriers (P trend = 0.17 and P trend = 0.07), but the HR estimates were in line with the ORs estimated for estrogen receptor-positive disease in the SEARCH study ( Table 3) .
All five SNPs were located in a region that spans 39 kb on 19p13 (Fig. 2) . In an analysis for the joint effect of these SNPs on breast cancer risk for BRCA1 carriers, it was not possible to distinguish between rs8170 and rs4808611, as neither SNP improved the model fit significantly when the other was included (P = 0.11 and P = 0.22 for rs8170 and rs4808611, respectively). rs8100241 was retained in preference to rs3745185 (P for inclusion of rs3745185 in model = 0.79). Thus, the most parsimonious model included SNPs rs8170 and either rs8100241 or rs2363956 (P for inclusion = 7.7 × 10 −5 and P = 6.7 × 10 −5 for rs8170 and rs8100241, respectively) and had a 2 d.f. P = 6.3 × 10 −13 for inclusion of both SNPs. This suggests that these associations may be driven by a single causative variant that is partially correlated with all five SNPs. To investigate this further, we evaluated the associations for SNPs identified through the 1000 Genomes Project using imputation. 1,055 SNPs in a 300-kb interval with a minor allele frequency >0.01 in samples of European ancestry, were evaluated. Thirty-one SNPs, none of which were genotyped in stage 1, displayed P < 1.76 × 10 −9 ( Fig. 2 and Supplementary Table 3) . The most significant associations with the imputed genotypes in stage 1 and 2 combined were for eight perfectly correlated SNPs within a 13-kb region (the most significant SNP was rs4808075, P = 9.4 × 10 −12 ; Supplementary Table 3) . These SNPs were correlated with the four l e t t e r s genotyped SNPs (r 2 = 0.37 to r 2 = 0.58 based on the 1000 Genomes Project data; Supplementary Fig. 2 ). This suggests that one or more of these imputed SNPs may be causally associated with breast cancer risk. However, some rare SNPs may have been missed because the 1000 Genome Project data used were based on the resequencing of only 56 individuals. Therefore, the possibility that the association is driven by a rarer variant, or a more cryptic common variant not detected in the resequencing, cannot yet be ruled out.
Of the five genotyped SNPs in the region and the eight most significant imputed SNPs, only rs8170 and rs2363956 were located in coding regions. The smaller 13-kb region, defined by the most strongly associated SNPs, contains three genes: ABHD8 (encoding abhydrolase domain containing 8), ANKLE1 (encoding ankyrin repeat and LEM domain containing 1) and C19orf62. The eight most significant imputed SNPs were clustered in and around ANKLE1, which encodes a protein of undefined function. However, C19orf62, which encodes MERIT40 (Mediator of Rap80 Interactions and Targeting 40 kD), is a more plausible genetic modifier of breast cancer in BRCA1 carriers because MERIT40 interacts with BRCA1 in a protein complex. MERIT40 is a component of the BRCA1 A complex containing BRCA1-BARD1, Abraxas1, RAP80, BRCC36 and BRCC45 that is required for recruitment and retention of the BRCA1-BARD1 ubiquitin ligase and the BRCC36 deubiquitination enzyme at sites of DNA damage [21] [22] [23] . Thus, a variant that modifies MERIT40 function or expression might influence BRCA1-dependent DNA repair and checkpoint activity in mammary epithelial cells of BRCA1 carriers sufficiently, before loss of the wildtype BRCA1 allele, to increase the risk of breast cancer. However, until the SNPs that increase risk of cancer have been definitively linked to MERIT40, it remains possible that the other genes in the region or genes influenced by long range chromatin remodeling or by transcriptional events account for the breast cancer association.
Genetic variation at this locus, in combination with other risk modifiers, may prove useful in individual cancer risk assessment for breast cancer in BRCA1 carriers. In addition, understanding the functional basis of this association may provide important insights into the etiology of BRCA1-associated breast cancer and hormone receptor-negative breast cancer in the general population. Our results suggest that GWAS in BRCA1 mutation carriers or GWAS restricted to specific breast cancer subtypes may identify further breast cancer susceptibility variants.
URLs. 1000 Genomes Project, http://www.1000genomes.org; MACH software, http://www.sph.umich.edu/csg/yli/mach/index.html/.
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Subjects. BRCA1 mutation carriers. Carriers of pathogenic mutations in BRCA1 used in stages 1 and 2 were drawn from 39 centers from North America, Europe and Australia. Thirty-six centers are participating in the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA). The majority of mutation carriers were recruited through cancer genetics clinics offering genetic testing and were enrolled into national or regional studies. The remainder of the carriers were identified by population-based sampling of cases or by community recruitment. Eligibility to participate was restricted to female carriers of pathogenic BRCA1 mutations who were 18-years-old or older at recruitment and who were of 'white' self-reported ancestry. Information collected included the year of birth; mutation description, including nucleotide position and base change; age at last follow up; ages at breast and ovarian cancer diagnosis; and age or date at bilateral prophylactic mastectomy. Information was also available on the country of residence, defined as the country of the clinic at which the carrier family was recruited to the study. Related individuals were identified through a unique family identifier. Carriers of unclassified variants of uncertain clinical significance were excluded. All carriers participated in clinical or research studies at the host institutions under ethically approved protocols.
Stage 1 sample selection. To improve power, stage 1 of the GWAS included BRCA1 mutation carriers diagnosed with breast cancer at a young age and older mutation carriers who had not developed the disease. We selected 1,250 carriers diagnosed with invasive breast cancer when younger than 40-years-old and 1,250 carriers who had not developed breast cancer or who had developed a first ovarian cancer when 35 years of age or older. Related pairs of individuals were eligible for inclusion in stage 1 if they were discordant with respect to their breast cancer disease status (211 pairs). Stage 1 mutation carriers resided in eleven different countries (Supplementary Table 2 ).
Stage 2 samples.
We selected stage 2 samples from the remaining BRCA1 mutation carriers from each participating center. Individuals who developed ductal carcinoma in situ (DCIS) were not eligible for inclusion in either stage 1 or stage 2. Carriers from an additional six countries were included in stage 2 (Supplementary Table 2) .
Population-based breast cancer cases and controls. Breast cancer cases were drawn from the Studies in Epidemiology and Risks of Cancer Heredity (SEARCH), an ongoing population based study of cancer patients ascertained through the East Anglian Cancer Registry in the UK. Eligible cases were those diagnosed with breast cancer under age 55 years between the years 1991 and 1996 and were still alive in 1996, and all incident breast cancer cases diagnosed under age 70 years between 1996 and 2006. Controls from the same geographical region were drawn at random from the European Prospective Investigation of Cancer (EPIC-Norfolk) cohort and from general practices recruiting patients to SEARCH. The majority of cases and controls were self reported as 'white' (>98% of the population) and were broadly of the same age. A more detailed description of these studies has been previously described 24 .
Both of these studies were approved by local ethical committees and participants gave written informed consent. Table 2 ).
All available controls were used; a categorical variable defined by center (for centers with both cases and controls) or country of residence (for centers contributing cases only combined with controls from other GWAS) was included as an adjustment variable in the primary analysis.
BRCA2 mutation carriers.
Carriers of pathogenic mutations in BRCA2 were drawn from an ongoing two-stage GWAS of genetic modifiers for BRCA2 mutation carriers. Individuals were recruited through 33 studies, which were largely the same as the studies that contributed to the BRCA1 GWAS and had similar eligibility criteria. Genotype data for the SNPs under investigation in this report were available only for the stage 2 samples of the BRCA2 GWAS (2,486 individuals in total).
Genotyping and quality control. BRCA1 mutation carrier samples. All BRCA1 DNA samples were assessed for quality and concentration by PicoGreen analysis and by visualization after electrophoresis in E-Gel (Invitrogen) agarose gels. Samples selected for stage 1 were genotyped at The Center for Applied Genomics, Children's Hospital of Philadelphia, using the Illumina Infinium 610K array. Of the 2,500 samples genotyped, 55 failed to produce genotyping data and were excluded from all further assessment. Of the 620,901 markers genotyped, 22,545 were excluded from subsequent quality control analysis because of low quality genotyping data (SNP call rate <90%), were Y-chromosome SNPs or were copy number variants. An iterative quality control process was applied to the remaining samples to exclude samples with low call rates (<99%), excess heterozygosity, sex errors and sample duplications, and to exclude SNPs with call rates <95%, minor allele frequencies <0.01, minor allele frequencies between 0.01 and 0.05 and call rate <0.98, or Hardy-Weinberg equilibrium P < 10 −7 ) in the entire sample (Supplementary Table 1 ). We further excluded individuals of non-European ancestry using multi-dimensional scaling. For this purpose we selected 37,804 autosomal SNPs that were not strongly correlated (pair-wise r 2 < 0.10). These SNPs were used to compute the genomic kinship between all pairs of BRCA1 mutation carriers in our sample, along with 210 HapMap samples (from the CHB, YRI and CEU populations). These were converted to distances (by subtracting from 0.5) and subjected to multidimensional scaling. Supplementary  Figure 1 shows a graphical representation of the first two components for all BRCA1 mutation carriers and for the subgroups defined by the common Ala185delGly BRCA1 Jewish founder mutation and the 5382insCys Eastern European founder mutation. Using the first two components, we calculated the proportion of European ancestry for each individual to be:
where x is the first principal component coordinate, y is the second component coordinate, and x i and y i represent the mean coordinates among the CHB (i = 1), YRI (i = 2) and CEU (i = 3) HapMap samples. Individuals with >15% non-European ancestry were excluded from the analysis. Genotyping. Non-BRCA1 samples. DNA samples from the SEARCH breast cancer subjects and regional controls were genotyped for SNPs rs8170 and rs2363956 using the 5′exonuclease assay (TaqMan) using the ABI Prism 7900HT sequence detection system. BRCA2 mutation carriers were genotyped using the Sequenom iPlex platform. A total of 1,385 TNBCC cases were genotyped for the five SNPs as part of an ongoing GWAS using the Illumina Infinium 660K array. Another 916 TNBCC cases were genotyped for rs8170, rs2363956 and rs4808611 by iPlex (Sequenom). The QIMR and CGEMS controls were genotyped using the Illumina Infinium 550K array, and the WTCCC controls were genotyped using a custom Illumina Infinium 1.2M array. More details of the genotyping in the control samples have been previously described [1] [2] [3] . Only observed genotypes for the five SNPs on 19p13 were used in the analyses.
Statistical methods. Analysis of genotype data from BRCA1 carriers. The main analyses were focused on the evaluation of associations between each genotype and breast cancer risk. The phenotype of each individual was defined by age at diagnosis of breast cancer or age at last follow up. For this purpose, individuals were censored at the age of the first breast cancer diagnosis, ovarian cancer diagnosis or bilateral prophylactic mastectomy, whichever occurred first, or at the age at last observation. Mutation carriers censored at ovarian cancer diagnosis were considered to be unaffected controls. Analyses were carried out within a survival analysis framework. Because mutation carriers were not sampled randomly with respect to their disease status, standard methods of survival analysis (such as Cox regression) may have led to biased estimates 26 . We therefore conducted the analysis by modeling the retrospective likelihood of the observed genotypes conditional on the disease phenotypes. The associations between genotype and breast cancer risk at both stages were assessed using the 1 d.f. score test statistic based on this retrospective likelihood as described previously 19 . This statistic has the form f where f kl is the kinship coefficient for the pair of individuals k and l, which can be estimated from the available genomic data 27, 28 . A robust variance approach using a Huber-White sandwich estimator, based on reported family membership, was also used for comparison purposes 29 . We chose to present the P values based on the kinship-adjusted score test as it utilizes the degree of relationship between individuals in our sample. P values based on the robust score test statistic are also quoted in Supplementary Table 3a . In practice, the differences in significance levels between the two methods were slight (with the kinship-adjusted P values being slightly less significant for the key SNPs). These analyses were performed in R using the GenABEL 30 and SNPMatrix 31 libraries, as well as custom-written functions.
To estimate the magnitude of the associations, the effect of each SNP was modeled either as a per-allele HR (multiplicative model) or as separate HRs for heterozygotes and homozygotes, and these effects were estimated on the log scale. The HRs were assumed to be independent of age (that is, we used a Cox proportional-hazards model). The retrospective likelihood was modeled in the pedigree-analysis software MENDEL 32 as previously described 19 . As sample sizes varied substantially between studies or contributing centers (including some with small numbers) heterogeneity was examined at the country level. This was assessed by comparing models that allowed for country-specific loghazard ratios against models in which the same log-hazard ratio was assumed to apply to all countries. All analyses were stratified by country of residence and used calendar year and cohort-specific breast cancer incidence rates for BRCA1 (ref.
2). The combined stage 1 and stage 2 analysis was also stratified by stage. Similar methods were used to assess the associations with breast cancer risk for BRCA2 mutation carriers.
To evaluate the combined effects of the significant SNPs on breast cancer risk, we fitted for each pair of SNPs retrospective likelihood models of the form where β 1 is the per-allele log-hazard ratio for SNP 1, β 2 is the per-allele loghazard ratio for SNP 2, and x 1 and x 2 represent the number of minor alleles at locus 1 and 2 respectively (for example, 0, 1 or 2), while at the same time allowing for linkage disequilibrium between the loci. To test whether the fit of the model was significantly improved by the inclusion of a locus into the model, we tested for the significance of parameters β 1 and β 2 .
